{"id":"vecuronium-atracurium","safety":{"commonSideEffects":[{"rate":null,"effect":"Histamine release (atracurium)"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Prolonged neuromuscular blockade"}]},"_chembl":{"chemblId":"CHEMBL1200629","moleculeType":"Small molecule","molecularWeight":"637.74"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are non-depolarizing neuromuscular blockers that bind to nicotinic acetylcholine receptors at the motor end plate, preventing acetylcholine from binding and triggering muscle contraction. Vecuronium is metabolized hepatically with intermediate duration of action, while atracurium undergoes Hofmann elimination and ester hydrolysis, making it independent of organ function. When used together, they provide combined neuromuscular blockade for surgical anesthesia.","oneSentence":"Vecuronium and atracurium are neuromuscular blocking agents that competitively inhibit acetylcholine at the neuromuscular junction, causing muscle paralysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:58.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Muscle relaxation during general anesthesia and mechanical ventilation in surgical procedures"},{"name":"Facilitation of endotracheal intubation"}]},"trialDetails":[{"nctId":"NCT04545424","phase":"PHASE2","title":"Trial of Therapeutic Hypothermia in Patients With ARDS","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2021-06-29","conditions":"Respiratory Distress Syndrome, Adult","enrollment":340},{"nctId":"NCT03376854","phase":"PHASE2","title":"Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2018-05-01","conditions":"Respiratory Distress Syndrome, Adult, Sars-CoV2","enrollment":""},{"nctId":"NCT03371953","phase":"PHASE4","title":"Evaluation of Atracurium-vecuronium Combination in Laparosocpic Surgery","status":"UNKNOWN","sponsor":"Sir Ganga Ram Hospital","startDate":"2017-12-20","conditions":"Patients Undergoing Laparoscopic Surgery","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vecuronium + Atracurium","genericName":"Vecuronium + Atracurium","companyName":"Sir Ganga Ram Hospital","companyId":"sir-ganga-ram-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vecuronium and atracurium are neuromuscular blocking agents that competitively inhibit acetylcholine at the neuromuscular junction, causing muscle paralysis. Used for Muscle relaxation during general anesthesia and mechanical ventilation in surgical procedures, Facilitation of endotracheal intubation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}